An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

SYFOVRE®

Drug Information Related Patent
Hold Company
APELLIS PHARMS
Learn More
Dosage and Administration
SOLUTION;INTRAVITREAL
Specification
15MG/0.1ML (15MG/0.1ML)
Indication
SYFOVRE® is used in the treatment of age-related macular degeneration (AMD) secondary geographic atrophy (GA).
Use
Instructions for Use
API
PEGCETACOPLAN
API Structure
We Supply
PEGCETACOPLAN
Note:

null

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
100358222033/11/15
101251712033/8/2
108758932033/11/15
112928152033/11/15
116614412033/1/13
78883232027/12/4
79895892027/12/4
81685842027/4/7
90560762026/10/25
91693072027/11/18
API Patent
Patent NoExpiration Date
78883232027/12/4
79895892027/12/4
91693072027/11/18
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top